Teva Pharmaceuticals has initiated a voluntary recall of two drugs for the treatment of high blood pressure for a potential cancer risk.

In a statement by Teva published by the Food and Drug Administration the recall concerns all combinations of tablets with the drugs amlodipine and valsartan and another combination preparation with amlodipine, valsartan and hydrochlorothiazide.

The drugs may contain a contaminant called N-nitroso-diethylamine (NDEA), which is considered potentially carcinogenic, according to the FDA.

Patients who are either taking medication should consult their doctor or pharmacist for advice or alternative treatments. Immediate discontinuation of medications without a comparable alternative could pose a greater risk to patient health, Teva said.

Customers and patients with questions can contact Teva at 888-838-2872 or by email at druginfo@tevapharm.com.

In August, the FDA announced an extended recall of valsartan as products may contain the contaminant. Two more recalls were announced last month: one for the drug irbesartan and a second for losartan potassium hydrochlorothiazide tablets.

In an interview with USA TODAY in November, FDA Commissioner Scott Gottlieb said the blood pressure drugs reflect an increased focus

Follow Brett Molina on Twitter: @ brettmolina23 .

Read or Share This Story: https://www.usatoday.com/story/news/health/ 2018/11/30 / Blood Pressure Medications-Two-more-Medications-Recognized Cancer Risk / 2159850002 /